Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer’s Disease Portfolio at CTAD 2026

• Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers
• Phase III PrevenTRON study design specifics for trontinemab in preclinical Alzheimer’s disease, which has commenced enrollment
• Phase II TARBELA-AD study design for the investigational oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease, representing a novel mechanism of action targeting neuroinflammation
• Global clinical and health economic data on the Elecsys^® pTau217 and Elecsys pTau181 blood tests supporting accessible, timely diagnosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will present new data across its pharmaceuticals and diagnostics portfolios at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Congress, taking place in Boston from November 16-19, 2026. Across 16 accepted abstracts, including two scientific symposia and two oral presentations, Genentech and Roche will highlight its differentiated approach to neurodegeneration: uniting high-accuracy diagnostic testing with targeted investigational therapeutics to address the disease across its continuum.

Expanding its Alzheimer’s disease pipeline, Genentech and Roche are initiating a new Phase II clinical trial, TARBELA-AD, evaluating an investigational oral NLRP3 inhibitor, RG6434, in early symptomatic Alzheimer’s disease. The study underscores Genentech and Roche's multi-pronged strategy to target distinct biological mechanisms, investigating neuroinflammation as a critical driver of pathology alongside amyloid aggregation.

“Amyloid clearance remains a vital foundation, but halting a disease as complex as Alzheimer’s demands multifaceted and complementary strategies," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "By advancing our Phase II TARBELA-AD trial evaluating an NLRP3 inhibitor, alongside ongoing trontinemab programs, we will test additional therapeutic hypotheses to potentially stop or prevent disease progression."

Roche’s diagnostics division continues to expand access to earlier and more accurate diagnosis of Alzheimer’s through its comprehensive blood-based biomarker portfolio, including the approved Elecsys^® pTau217 and Elecsys pTau181 tests.

“Transforming care for Alzheimer’s disease begins with bringing clarity to individuals and families as early as possible," said Matt Sause, CEO of Roche Diagnostics. "Elecsys pTau217 is the first and only FDA-cleared, single biomarker blood test that both rules in and rules out amyloid pathology. By expanding assessment into primary care as well as specialist settings, it can deliver fast, accurate answers so people can evaluate treatment and plan for the future."

Pharmaceuticals

Scientific symposia will feature the latest research on investigational trontinemab and NLRP3 inhibition:

• Monday, November 16 at 4:50-5:30 PM ET: “Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab” will provide the latest neuroimaging, pharmacokinetics/pharmacodynamics and safety data from the Phase Ib/IIa Brainshuttle™ AD study, which is evaluating the potential of trontinemab to provide rapid and robust amyloid clearance in Alzheimer’s disease.
• Tuesday, November 17 at 2:35-3:15 PM ET: “Neuroinflammation in Alzheimer’s Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk” will explore neuroinflammation in Alzheimer’s disease and early data on targeting the NLRP3 inflammasome with RG6434.

Keynote address by Geoff Kerchner, Global Head of Neurodegeneration Product Development at Roche:

• Tuesday, November 17 at 9:10-9:35 AM ET: “A glimpse of the future: How diagnostics, therapies, trials, and concepts of prevention must evolve” will explore the interplay between these themes to crystallize a vision for what the future could look like, and what we need to do now to realize it.

An oral presentation will provide a deep dive into the Phase III PrevenTRON study of trontinemab in preclinical Alzheimer’s disease:

• Wednesday, November 18 at 9:55-10:05 AM ET: “PrevenTRON: Evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer’s disease at high risk of clinical decline” will detail the study design and participant screening for the PrevenTRON study, which has recently started enrolling participants.

Diagnostics

Across multiple posters, available to view from Monday, November 16 at 9:00 AM ET, Roche will present new clinical, health economic and real-world data for its latest blood tests, including Elecsys pTau217 and Elecsys pTau181, across diverse global patient populations and care settings to support Alzheimer’s diagnosis. Key presentations will explore the impact of integrating blood-based pTau217 testing into routine clinical practice on healthcare economics and efficiency of diagnostic pathways.

Overview of CTAD presentations featuring Genentech and Roche pharmaceuticals and diagnostics:

Topic	Abstract title	Presentation number (type)   Presentation date (session)   Time (ET)   Location within Marriott Copley Place
Abstracts will be available on the CTAD website.
Trontinemab	Trontinemab in Alzheimer’s disease – novel pharmacodynamic insights from the ongoing Phase Ib/IIa Brainshuttle™ AD study	Symposium 1 (3 Orals)   Monday, November 16 (Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab)   4:50-5:30 PM   Grand Ballroom
	Advanced imaging results from the Brainshuttle™ AD study with trontinemab in Alzheimer’s disease
	Brain delivery and distribution of the novel Brainshuttle™ Aβ-targeting antibody trontinemab in participants with Alzheimer’s disease measured with ^89Zr positron emission tomography
	PrevenTRON: Evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer’s disease at high risk of clinical decline	OC23 (Oral)   Wednesday, November 18 (Oral Communications: Session on Study Design and Phase I/Phase IIa Studies)   9:55-10:05 AM   Grand Ballroom
NLRP3 & RG6434	The NLRP3 inflammasome as a therapeutic target in Alzheimer’s disease: biomarker, preclinical evidence and Phase I healthy participants’ safety data of the oral inhibitor RG6434	Symposium 4, Presentation 3 (Oral)   Tuesday, November 17 (Neuroinflammation in Alzheimer’s Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk)   2:35-3:15 PM   Grand Ballroom
	Rationale and design of TARBELA-AD: A Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease	P016 (Poster)   Monday, November 16 at 2:00 PM to Tuesday, November 17 at 5:30 PM (Poster Session 1: Clinical Trials – Phase IIb & III)   Poster Hall
Alzheimer’s disease area	A glimpse of the future: How diagnostics, therapies, trials, and concepts of prevention must evolve	Keynote 2 (Keynote address)   Tuesday, November 17   9:10-9:35 AM   Grand Ballroom
	Advancing Alzheimer’s Disease Clinical Trials Through the Critical Path for Alzheimer’s Disease Consortium (CPAD)	P390 (Poster)   Thursday, November 19 (Poster Session 3: Trial Design, Statistical Innovation, and Analytical Frameworks)   7:15 AM – 5:00 PM   Poster Hall
	Clinical and operational determinants of amyloid-targeting therapies treatment initiation in early Alzheimer’s Disease: A discrete choice experiment	P394 (Poster)   Thursday, November 19 (Poster Session 3: Trial Design, Statistical Innovation, and Analytical Frameworks)   7:15 AM – 5:00 PM   Poster Hall
	REACHED: Participant characteristics from a pilot pre-screening study designed to diversify clinical trial recruitment in understudied populations in Alzheimer’s disease	P437 (Poster)   Thursday, November 19 (Poster Session 3: Digital Endpoints, Remote Monitoring, and Connected Health Tools)   7:15 AM – 5:00 PM   Poster Hall
Diagnostics	Clinical Impact of Introducing Blood-Based pTau217 Testing in Canadian Alzheimer’s Disease Diagnostic Pathways: Initial Results from a Localized Clinical Simulation Model	P240 (Poster)   Wednesday, November 18 (Poster Session 2: Biomarkers [CSF & Plasma])   7:15 AM – 5:30 PM   Poster Hall
	Validation of Elecsys pTau217 plasma assay cutoffs for detection of amyloid pathology across care settings	P261 (Poster)   Wednesday, November 18 (Poster Session 2: Biomarkers [CSF & Plasma])   7:15 AM – 5:30 PM   Poster Hall
	Mitigating amyloid endpoint heterogeneity to establish robust cutoffs and clinical performance of Elecsys pTau217 and pTau181 plasma immunoassays	P262 (Poster)   Wednesday, November 18 (Poster Session 2: Biomarkers [CSF & Plasma])   7:15 AM – 5:30 PM   Poster Hall
	Diagnostic accuracy of Elecsys pTau181 and pTau217 plasma assays using global cutoffs in an Asian cohort: Results from the K-ROAD registry	P265 (Poster)   Wednesday, November 18 (Poster Session 2: Biomarkers [CSF & Plasma])   7:15 AM – 5:30 PM   Poster Hall
	Elecsys pTau217 plasma assay cutoff determination and validation for the detection of amyloid pathology in a Chinese population	P277 (ePoster)   (Virtual Poster: Biomarkers [CSF & Plasma])
	Diagnostic accuracy of the automated Elecsys CSF Aβ42/Aβ40 ratio and Aβ42 in a population reflective of clinical practice	P226 (ePoster)   (Virtual Poster: Biomarkers [CSF & Plasma])
	Re-evaluating TDP-43 assays: Hemolysis interference limits clinical utility	P291 (ePoster)   (Virtual Poster: Biomarkers [CSF & Plasma])
	Optimizing the Alzheimer’s disease diagnostic pathway: An economic evaluation of a pTau217 blood-based biomarker in primary and specialist care in the U.S.	P292 (Poster)   Wednesday, November 18 (Poster Session 2: Biomarkers [CSF & Plasma])   7:15 AM – 5:30 PM   Poster Hall
	ROAD-US: an evaluation of the utilization and clinical utility of Alzheimer’s disease blood biomarkers in U.S. community practices, a pre-post time series study	P485 (Poster)   Thursday, November 19 (Poster Session 3: Real-World Data, Registries & Implementation Science)   7:15 AM – 5:00 PM   Poster Hall

About Genentech and Roche in Alzheimer’s

For nearly 30 years, Genentech and Roche have been working towards a day when we can detect and treat Alzheimer’s earlier, in order to slow, stop or even prevent its progression by combining our expertise across pharmaceuticals and diagnostics.

Today, Genentech and Roche’s Alzheimer’s disease portfolio spans investigational medicines targeting complementary biological pathways, from amyloid to neuroinflammation, with candidates such as trontinemab, nivegacetor and RG6434. Genentech and Roche are also advancing innovative approaches to drug delivery through Brainshuttle™ technology, designed to enhance the transport of medicines across the blood–brain barrier.

Roche’s diagnostics division offers an industry-leading portfolio of approved products spanning cerebrospinal fluid (CSF) assays and blood-based tests, including Elecsys pTau181, pTau217 and ApoE4. Roche also maintains a comprehensive portfolio of research use only (RUO) tests, providing early access to new biomarkers to empower researchers to shape tomorrow’s diagnostics.

Addressing the global burden of Alzheimer’s disease requires more than innovative tests and treatments. This is why Genentech and Roche partner across the healthcare ecosystem with clinicians, scientists, patient advocates, policymakers and health systems to help simplify the care pathway and ensure advances in research translate into real-world benefits for millions worldwide.

About Genentech

Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.